Drug
Dabrafenib
Dabrafenib: highest development phase Post-Market, developed by Novartis. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| dabrafenib NCT03340506 | Post-Market | Melanoma |
| TAFINLAR | Approved |
Latest
Follow Dabrafenib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.